In a report released on November 20, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on CureVac (CVAC – Research Report), with a price target of $8.00. The company’s shares opened today at $5.52.
Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and Moderna. According to TipRanks, Papadakis has an average return of 5.3% and a 56.77% success rate on recommended stocks.
CureVac has an analyst consensus of Strong Buy, with a price target consensus of $14.75.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $12.79 and a one-year low of $4.95. Currently, CureVac has an average volume of 444.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CureVac (CVAC) Company Description:
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company’s product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
Read More on CVAC:
